Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (121)	3/8/1998 9:08:00 PM
From: BDR	Read Replies (2) \| Respond to of 1016

I don't know this journal but it doesn't sound like it is peer reviewed and it may not have a wide readership. Anybody know? One reason the article may not have mentioned the side effects is because we don't know what the FDA is going to require Pfizer to list as significant side effects until we get the approval. I agree that Cacaito's post implied that this was a front for Pfizer despite his disclaimer that that inference was read into his post by others. << No wonder Leland went out and talk about the massive competition from Pfizer.>> Was Leland (and Cacaito) surprised that Pfizer was going to compete on a massive scale? VVUS should have been bracing for this from the first mention of sildenafil a couple of years ago. Let's see- production problems, plant approval problems, company stumbles with major ad campaign, company (and longs) surprised at a quarterly loss, surprised that Pfizer is a competitive drug company, HVSF is granted a patent for its lyophilized product and announces that it is stable for up to nine months at room temperature.... I am sure the spin doctors have choked on all this. I agree that MUSE, though maybe not VVUS, will be around in the future, but who would buy this stock at this particular time?